SCHEMBL8210224

SCHEMBL8210224

CC(C)C[C@H](N)C(=O)N1CCC(=NOCc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.47
HDAC8 Q9BY41 2/20 0.42
KMT2A Q03164 1/20 0.42
DPP7 Q9UHL4 5/20 0.41
HRH1 P35367 1/20 0.40
SLC6A15 Q9H2J7 1/20 0.40
ANPEP P15144 1/20 0.39
RNPEP Q9H4A4 1/20 0.39
DNPEP Q9ULA0 1/20 0.39
FNTA P49354 1/20 0.39
PGGT1B P53609 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GAA P10253 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP4 P27487 1/20 0.39
KCNH2 Q12809 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4379113 0.99 CACNA1B (0.47) CACNA1BHDAC8KMT2ADPP7HRH1
Hydrochloric Acid SCHEMBL4379106 0.99 CACNA1B (0.47) CACNA1BHDAC8KMT2ADPP7HRH1
SCHEMBL8210932 0.87 HDAC8 (0.56) HDAC8DPP7DPP8DPP4OPRK1
Hydrochloric Acid SCHEMBL4381745 0.86 HDAC8 (0.58) HDAC8DPP7DPP8DPP4OPRK1
Hydrochloric Acid SCHEMBL4381750 0.86 HDAC8 (0.58) HDAC8DPP7DPP8DPP4OPRK1
SCHEMBL8225043 0.84 DPP4 (0.43) KMT2ADPP7ANPEPRNPEPDNPEP
SCHEMBL13588914 0.84 CTSK (0.48) CACNA1B
Hydrochloric Acid SCHEMBL4379532 0.84 LMNA (0.47) KMT2AGAA
Hydrochloric Acid SCHEMBL4379539 0.84 LMNA (0.47) KMT2AGAA
Hydrochloric Acid SCHEMBL4386043 0.84 DPP4 (0.42) HDAC8KMT2AANPEPRNPEPDNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 CACNA1B 28/4885HDAC8 3129/4885KMT2A 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.